Cargando…

Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials

BACKGROUND: At ketamine and esketamine doses at which antidepressant doses are achieved, these agents are relatively selective, noncompetitive, N-methyl-D-aspartate receptor antagonists. However, at substantially higher doses, ketamine has shown mu-opioid receptor (MOR–gene symbol: OPRM1) agonist ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saad, Ziad, Hibar, Derrek, Fedgchin, Maggie, Popova, Vanina, Furey, Maura L, Singh, Jaskaran B, Kolb, Hartmuth, Drevets, Wayne C, Chen, Guang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Regular Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710914/ https://www.ncbi.nlm.nih.gov/pubmed/32367114 http://dx.doi.org/10.1093/ijnp/pyaa030

Ejemplares similares

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
por: Chen, Guang, et al.
Publicado: (2022)

Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
por: Doty, Richard L., et al.
Publicado: (2021)

Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
por: Jamieson, Carol, et al.
Publicado: (2023)

Association of opioid receptor mu 1 (OPRM1) A118G polymorphism (rs1799971) with nicotine dependence
por: Kong, Xiangyi, et al.
Publicado: (2017)

Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
por: Floden, Lysbeth, et al.
Publicado: (2022)

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study
por: Morrison, Randall L., et al.
Publicado: (2018)

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
por: Fedgchin, Maggie, et al.
Publicado: (2019)

Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
por: Zaki, Naim, et al.
Publicado: (2023)

Lack of associations of the opioid receptor mu 1 (OPRM1) A118G polymorphism (rs1799971) with alcohol dependence: review and meta-analysis of retrospective controlled studies
por: Kong, Xiangyi, et al.
Publicado: (2017)

Association between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response
por: Xie, Xiaohu, et al.
Publicado: (2022)

The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder
por: Daly, Ella J., et al.
Publicado: (2021)

Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
por: Katz, Eva G., et al.
Publicado: (2020)

Genome-wide association study and polygenic risk score analysis of esketamine treatment response
por: Li, Qingqin S., et al.
Publicado: (2020)

Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD
por: Williamson, David, et al.
Publicado: (2022)

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
por: Doherty, Teodora, et al.
Publicado: (2020)

The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study
por: van de Loo, Aurora J. A. E., et al.
Publicado: (2017)

Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
por: Borentain, Stephane, et al.
Publicado: (2021)

Managing dissociative symptoms following the use of esketamine nasal spray: a case report
por: Pereira, Sophia, et al.
Publicado: (2020)

Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report
por: Vendrell-Serres, Júlia, et al.
Publicado: (2021)

Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression
por: Drevets, Wayne C., et al.
Publicado: (2008)

Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
por: Bossaller, Nicholas A., et al.
Publicado: (2020)

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior
por: Canuso, Carla M., et al.
Publicado: (2021)

ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression
por: Ludovic, S., et al.
Publicado: (2022)

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
por: Ionescu, Dawn F, et al.
Publicado: (2020)

Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data
por: Nijs, Michel, et al.
Publicado: (2020)

Opiates and Anæsthetics
Publicado: (1888)

Not Opiates but Antiphlogistine
Publicado: (1903)

The Opiate Dilemma
por: Jeffrey, Paul L., et al.
Publicado: (2014)

The frequency of DRD2 rs1076560 and OPRM1 rs1799971 in substance use disorder patients from the United Arab Emirates
por: Alblooshi, Hiba, et al.
Publicado: (2018)

A novel tetra-primer ARMS-PCR for genotyping of the OPRM1 gene rs1799971 variant associated with opioid use disorders
por: Wijekumar, P. J., et al.
Publicado: (2023)

Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent
por: AL-Eitan, Laith N, et al.
Publicado: (2012)

Targeted Expression of Mu-Opioid Receptors in a Subset of Striatal Direct-Pathway Neurons Restores Opiate Reward
por: Cui, Yijun, et al.
Publicado: (2014)

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

ESKALE study, a French real-world study describing TRD patients with Esketamine nasal spray: final analysis
por: Samalin, L., et al.
Publicado: (2023)

Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine
por: Borentain, Stephane, et al.
Publicado: (2022)

CLONIDINE IN OPIATE DETOXIFICATION
por: Gangadhar, B.N., et al.
Publicado: (1982)

CLONIDINE FOR OPIATE WITHDRAWAL
por: Subramanya,, et al.
Publicado: (1981)

Opiate and Cerebral Atrophy
por: Zirpe, Kapil, et al.
Publicado: (2020)

Endogenous opiates: 1993
por: Olson, Gayle A., et al.
Publicado: (1994)

Hypo-Substitute for Opiates
Publicado: (1899)

Cannot write session to /tmp/vufind_sessions/sess_tvo1ibc44nbg3ni958kk7fepjg